Balance Sheet
Cash Flow Statement
AmortizationAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Change in Cash (2016 - 2025)

Historic Change in Cash for Dr Reddys Laboratories (RDY) over the last 17 years, with Q4 2025 value amounting to $94.2 million.

  • Dr Reddys Laboratories' Change in Cash rose 35419.18% to $94.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $50.3 million, marking a year-over-year decrease of 7424.79%. This contributed to the annual value of $85.0 million for FY2025, which is 40000.0% up from last year.
  • Latest data reveals that Dr Reddys Laboratories reported Change in Cash of $94.2 million as of Q4 2025, which was up 35419.18% from $8.1 million recorded in Q3 2025.
  • In the past 5 years, Dr Reddys Laboratories' Change in Cash registered a high of $160.2 million during Q4 2021, and its lowest value of -$202.7 million during Q4 2023.
  • For the 5-year period, Dr Reddys Laboratories' Change in Cash averaged around $7.6 million, with its median value being $17.0 million (2025).
  • Its Change in Cash has fluctuated over the past 5 years, first soared by 565549.0% in 2021, then tumbled by 54832.05% in 2023.
  • Quarter analysis of 5 years shows Dr Reddys Laboratories' Change in Cash stood at $160.2 million in 2021, then plummeted by 119.52% to -$31.3 million in 2022, then tumbled by 548.32% to -$202.7 million in 2023, then skyrocketed by 110.24% to $20.8 million in 2024, then surged by 354.19% to $94.2 million in 2025.
  • Its Change in Cash was $94.2 million in Q4 2025, compared to $8.1 million in Q3 2025 and -$67.4 million in Q2 2025.